TABLE 1.

Clinical and Molecular Characteristics of the Patients

Patient	Age (y)/Gender	ABCA4 Mutation	Visual Acuity*		Refraction†		Kinetic Visual Field Extent (V-4e)‡		Lutein Trial Participant?
			RE	LE	RE	LE	RE	LE
1	14/M	G863A/R943Q	20/32	20/32	−0.50	−0.50	109	105	Y
2	17/F	E1087K/G1961E	20/25	20/25	−1.00	−1.25	103	104	N
3	18/M	IVS48+21C>T	20/20	20/125	−1.00	−1.00	126	105	N
4§	19/F	R1129L/L1940P	20/40	20/50	+0.25	+0.25	90	93	Y
5	21/M	P1511del1ccgC/R1705Q	20/25	20/25	−0.75	−0.25	103	107	Y
6	24/M	T1019M/G1961E	20/50	20/200	−1.25	−1.50	112	105	Y
7§	26/M	∥	20/40	20/32	+1.00	+0.75	86	88	Y
8	30/F	∥	20/50	20/40	+2.25	+1.75	105	110	Y
9	30/M	R1108C/R152Q	20/20	20/32	−2.25	−3.50	99	93	Y
10	32/F	V935A/IVS40+5G>A	20/32	20/40	−0.75	−1.25	103	92	N
11	34/F	R681X/R1300Q	20/20	20/20	−1.50	−1.75	110	96	N
12	37/M	C54Y/G1961E	20/32	20/25	−3.00	−2.00	99	105	Y
13#	38/F	V256V/G1961E	20/25	20/25	−1.00	−1.25	106	101	Y
14#	42/F	V256V/G1961E	20/25	20/32	−0.50	−0.75	107	94	Y
15	47/F	R1300Q/R2107H	20/32	20/20	+0.75	+0.25	108	103	N
16§	49/M	∥	20/32	20/32	−4.50	−4.50	84	79	Y
17	56/M	G1977S	20/25	20/25	−5.50	−5.50	99	109	N

^*Best corrected visual acuity.

^†Spherical equivalent.

^‡Expressed as a percentage of normal mean of V-4e target; 2 SD below normal equals 90%.

^§Clinical diagnosis of cone-rod dystrophy; remaining patients had a clinical diagnosis of Stargardt disease.

^∥Mutation unknown.

^#Patients are siblings.